Figure 7A shows that CD36 mRNA expression was increased in the livers of NAFLD patients and was correlated with high SLC9A6‐126aa expression, suggesting that SLC9A6‐126aa may mediate CD36 transcription and contribute to NAFLD progression. This evidence concerns the gene SLC9A6 and metabolic dysfunction-associated steatotic liver disease.